医学
来氟米特
类风湿性关节炎
重症监护医学
磺胺吡啶
抗风湿药物
羟基氯喹
生物药物
疾病
生活质量(医疗保健)
抗风湿药
托珠单抗
甲氨蝶呤
内科学
溃疡性结肠炎
传染病(医学专业)
护理部
2019年冠状病毒病(COVID-19)
作者
Aliki I. Venetsanopoulou,Paraskevi V. Voulgari,Drosos Aa
标识
DOI:10.1080/14656566.2023.2297798
摘要
Rheumatoid arthritis (RA) is a complex autoimmune disease that affects millions of people worldwide, with a systemic impact. This review explores the role of non-biological conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in its management.We discuss the effectiveness and safety of key csDMARDs such as Nonsteroidal anti-inflammatory drugs, corticosteroids, Hydroxychloroquine, Sulfasalazine, Methotrexate, and Leflunomide in relieving symptoms and slowing the progression of the disease. We also highlight the importance of combination therapy using csDMARDs, supported by clinical studies demonstrating the benefits of various csDMARD combinations. Early intervention with these drugs is emphasized to prevent joint damage, improve clinical symptoms, and enhance patient outcomes.Overall, csDMARDs have proven pivotal in managing RA, providing cost-effective and versatile treatment options. We acknowledge the advantages of biologics but highlight the associated challenges, making the choice between non-biological and biological drugs a personalized decision. This comprehensive overview aims to provide a deeper understanding of RA treatment strategies, contributing to improving the quality of life for patients with this chronic condition.
科研通智能强力驱动
Strongly Powered by AbleSci AI